Nov 07, 2024 / 01:00PM GMT
Unidentified
(Audio in progress) Important risk factors that could cause our actual performance and results to differ materially from those expressed or implied in these forward-looking statements. I will now turn the call over to Stéphane are trued up enough.
Stephane Bancel - Moderna Inc - Chief Executive Officer, Director
Good morning or good afternoon, everyone. Thank you for joining us for ourselves. We will review of our business in the fourth quarter. Jamey will present our financial results and outlook, Stephen will review our clinical programs. I will then come back and share of key priorities before Q&A.
We did a good $1.9 billion of revenue in the third quarter. Net income was $13million barrels. We ended the quarter with cash and investments of $9.2 billion. As you know, formulary and now we have been working to improve productivity in the Company in the third quarter of 2024 compared to Q1 of 2023, we reduced operating expenses by $500 million across cost of sales, R&D and SG&A. This figure excludes $1.4 billion of resizing charge in
Q3 2024 Moderna Inc Earnings Call Transcript
6 days ago
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers